scispace - formally typeset
Open AccessJournal ArticleDOI

Cytokines in CAR T Cell-Associated Neurotoxicity.

Reads0
Chats0
TLDR
In this article, the authors systematically review reported correlations of secreted inflammatory mediators in the serum/plasma and cerebrospinal fluid with the risk of ICANS in patients receiving CAR T cell therapy.
Abstract
Chimeric antigen receptor (CAR) T cells provide new therapeutic options for patients with relapsed/refractory hematologic malignancies. However, neurotoxicity is a frequent, and potentially fatal, complication. The spectrum of manifestations ranges from delirium and language dysfunction to seizures, coma, and fatal cerebral edema. This novel syndrome has been designated immune effector cell-associated neurotoxicity syndrome (ICANS). In this review, we draw an arc from our current understanding of how systemic and potentially local cytokine release act on the CNS, toward possible preventive and therapeutic approaches. We systematically review reported correlations of secreted inflammatory mediators in the serum/plasma and cerebrospinal fluid with the risk of ICANS in patients receiving CAR T cell therapy. Possible pathophysiologic impacts on the CNS are covered in detail for the most promising candidate cytokines, including IL-1, IL-6, IL-15, and GM-CSF. To provide insight into possible final common pathways of CNS inflammation, we place ICANS into the context of other systemic inflammatory conditions that are associated with neurologic dysfunction, including sepsis-associated encephalopathy, cerebral malaria, thrombotic microangiopathy, CNS infections, and hepatic encephalopathy. We then review in detail what is known about systemic cytokine interaction with components of the neurovascular unit, including endothelial cells, pericytes, and astrocytes, and how microglia and neurons respond to systemic inflammatory challenges. Current therapeutic approaches, including corticosteroids and blockade of IL-1 and IL-6 signaling, are reviewed in the context of what is known about the role of cytokines in ICANS. Throughout, we point out gaps in knowledge and possible new approaches for the investigation of the mechanism, prevention, and treatment of ICANS.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

TL;DR: In this article, the authors compared the efficacy and toxicity profiles associated with CARs containing either CD28 or 4-1BB costimulatory domains and found that the rates of neurological toxicities were higher with CD28-costimulated CARs, although this finding is probably the result of a combination of factors rather than due to CD28 signalling alone.
Journal ArticleDOI

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.

TL;DR: In this article, the authors discuss how allogeneic CAR T cells could allow for multivalent approaches and alteration of the tumor microenvironment, potentially allowing the development of next generation therapies for the treatment of patients with GBM.
Journal ArticleDOI

Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.

TL;DR: In this paper, the authors summarized the mechanisms underlying CRS and ICANS and provided potential treatment and prevention strategies for CAR T-cell therapy, and proposed a treatment strategy for CRS.
Journal ArticleDOI

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies

TL;DR: McNerney et al. as mentioned in this paper showed that blocking IFNγ in CAR T cells does not impair their cytotoxicity against hematologic tumor cells and paradoxically enhances their proliferation and reduces macrophage-mediated cytokines and chemokines associated with CRS.
Journal ArticleDOI

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

TL;DR: This review focuses on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets,CAR-T related toxicities, and resistance to CAR- T cell therapy, and provides some practical recommendations.
References
More filters
Journal ArticleDOI

Acute lethal encephalopathy in systemic juvenile rheumatoid arthritis

TL;DR: A first patient with systemic juvenile rheumatoid arthritis is presented in which acute necrotizing encephalopathy developed as a complication of macrophage activation syndrome but not of Reye's syndrome.
Journal ArticleDOI

Comparison of the inflammatory response of brain microvascular and peripheral endothelial cells following infection with Neisseria meningitidis.

TL;DR: Peripheral and brain microvascular endothelial cells differentially release IL‐8, IL‐6 and MCP‐1 upon infection with Neisseria meningitidis, which is a critical event in the development of invasive meningococcal disease.
Book ChapterDOI

Neurotoxicities After CAR T-Cell Immunotherapy

TL;DR: Data from patients and animal models of neurotoxicity demonstrate high levels of key cytokines in the blood and cerebrospinal fluid, and monocyte/macrophage and endothelial cell activation with compromise of the blood-brain barrier appears to contribute to the pathogenesis.
Related Papers (5)
Trending Questions (2)
What specific cytokines are produced by CD8 CAR-T cells?

The specific cytokines produced by CD8 CAR-T cells are not mentioned in the paper. The paper discusses the production of IFNg by CAR T cells and its association with neurotoxicity, but does not provide information on other specific cytokines produced by CD8 CAR-T cells.

What are the different CAR T cytokines used in Breyanzi?

The provided paper does not mention the specific CAR T cytokines used in Breyanzi.